MNOV
HealthcareMediciNova, Inc.
$1.38
+$0.05 (+3.76%)
Jan 5, 2026
Price History (1Y)
Analysis
MediciNova, Inc. is a biotechnology company operating in the healthcare sector with a market capitalization of $67.82 million. It has 13 employees and operates within the industry. The company's revenue for the trailing twelve months (TTM) was $257,918. The financial health of MediciNova, Inc. indicates significant losses, as evidenced by a net income of -$12,010,330 and EBITDA of -$13,353,593 for the TTM period. Additionally, the company's operating margin is -2741.7%, and its profit margin is 0.0%. The return on equity (ROE) and return on assets (ROA) are also negative at -24.3% and -15.8%, respectively. On a positive note, the debt to equity ratio is 0.58, indicating manageable leverage. The valuation of MediciNova, Inc. is characterized by a forward P/E ratio of -4.31 and an EV/EBITDA of -2.65. The company's price to book ratio is 1.54, while its price to sales ratio stands at 262.96.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About MediciNova, Inc.
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. It is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. The company has a license agreement with Kyorin Pharmaceuticals for the development and commercialization of MN-166 and MN-001. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Visit website →Key Statistics
- Market Cap
- $67.82M
- P/E Ratio
- N/A
- 52-Week High
- $2.15
- 52-Week Low
- $1.13
- Avg Volume
- 1.02M
- Beta
- 0.52
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 13